8 results on '"Merli, C. E. M."'
Search Results
2. “Time is on my side”. Disease trajectory of vulvodynia: a systematic review with a narrative synthesis
- Author
-
Cetera, G. E., Merli, C. E. M., Facchin, F., Barbara, G., Caia, C., Libutti, G., and Boero, V.
- Published
- 2024
- Full Text
- View/download PDF
3. “Time is on my side”. Disease trajectory of vulvodynia: a systematic review with a narrative synthesis
- Author
-
Cetera, G. E., primary, Merli, C. E. M., additional, Facchin, F., additional, Barbara, G., additional, Caia, C., additional, Libutti, G., additional, and Boero, V., additional
- Published
- 2023
- Full Text
- View/download PDF
4. “Time is on my side”. Disease trajectory of vulvodynia: a systematic review with a narrative synthesis
- Author
-
Cetera, G. E., Merli, C. E. M., Facchin, Federica, Barbara, G., Caia, C., Libutti, G., Boero, V., Facchin F. (ORCID:0000-0001-8944-1440), Cetera, G. E., Merli, C. E. M., Facchin, Federica, Barbara, G., Caia, C., Libutti, G., Boero, V., and Facchin F. (ORCID:0000-0001-8944-1440)
- Abstract
PurposeThe aim of this systematic review was to shed light on the disease-trajectory of vulvodynia and identify potential risk factors which may affect such trajectory.MethodsWe searched Pubmed to identify articles providing evidence on vulvodynia trajectory (i.e., remission, relapse or persistence rates) with a minimum follow-up of 2 years. A narrative approach was used for data synthesis.ResultsFour articles were included (total participants: 741 women with vulvodynia; 634 controls). At a 2-year follow-up, 50.6% of women reported remission, remission with relapse was observed in 39.7% and persistence throughout time occurred in 9.6%. A decrease in pain was observed in 71.1% of patients at a 7-year follow-up. Mean pain scores and depressive symptoms resulted lower at 2-year follow-up, whereas sexual function and satisfaction were increased. Factors associated with remission of vulvodynia were greater couple cohesion, decreased reporting of pain after intercourse and lower levels of worst pain. Risk factors for symptom persistence included marriage, more severe pain ratings, depression, pain with partner touch, interstitial cystitis, pain with oral sex, fibromyalgia, older age and anxiety. Recurrence was associated with: longer duration of pain, more severe ratings of the worst pain ever and pain described as provoked.ConclusionsSymptoms of vulvodynia seem to improve over time, regardless of treatment. This finding contains a key message for patients and their physicians, considering the deleterious consequences of vulvodynia on women's lives.
- Published
- 2023
5. “The sound of silence” Giving voice to endometriosis-related positional dyspareunia
- Author
-
Merli, C. E. M., Cetera, G. E., Caia, C., Facchin, Federica, Vercellini, P., Facchin F. (ORCID:0000-0001-8944-1440), Merli, C. E. M., Cetera, G. E., Caia, C., Facchin, Federica, Vercellini, P., and Facchin F. (ORCID:0000-0001-8944-1440)
- Abstract
Deep dyspareunia is one of the main symptoms of endometriosis. It appears to be submerged by a two-way disconnection between patients and their physicians. The aim of our review is to provide clear, ready-to-use advice on how to manage deep dyspareunia overcoming the gap in communication. Sexual history should always be taken as part of routine health care in these regards, using a patient-centered approach. An educational pelvic examination, which actively includes patients in the identification of painful areas, may prove useful to improve patients’ understanding of their condition. Correlating painful pelvic areas with sexual positions and inviting patients to adopt alternative positions may represent a simple but extremely effective coping strategy to mitigate pain. Revealing and explaining to partners the nature of the pain is essential to allow them to take part in shared research of coping mechanisms, empowering the couple to make choices and changes. Couples who do not feel comfortable talking about intimacy by themselves may find that including a psychotherapist or a sexual therapist, may be a good way to start communication. Investigating and managing dyspareunia during medical encounters is a medical and ethical duty all healthcare practitioners should pursue.
- Published
- 2023
6. Central Sensitization in Vulvodynia and Endometriosis: What Have We Been Overlooking So Far?
- Author
-
Cetera, G. E., Merli, C. E. M., Boero, V., Caia, C., Facchin, Federica, Barbara, Giovanni, Monti, E., Vercellini, P., Facchin F. (ORCID:0000-0001-8944-1440), Barbara G., Cetera, G. E., Merli, C. E. M., Boero, V., Caia, C., Facchin, Federica, Barbara, Giovanni, Monti, E., Vercellini, P., Facchin F. (ORCID:0000-0001-8944-1440), and Barbara G.
- Abstract
Importance Women experience more frequent and greater pain than men, although they receive less adequate treatment and are perceived as more anxious than males. Recent clinical research has lead to hypothesize a common etiology for overlapping chronic pain conditions and mood disorders, namely, central sensitization, which originates from an alteration of pain processing pathways in the central nervous system. Objective The aim of this review was to collect all available evidence regarding the potential role of central sensitization in vulvodynia and endometriosis. Evidence Acquisition A systematic literature search was performed between July and August 2022 using the electronic database PubMed. The extracted data were summarized using a narrative approach. Results Ten articles were chosen for the review. Participants' mean age was 39.2 years (SD = 5.1). Among serum markers of central sensitization, nitric oxide levels were greater in women with endometriosis than in controls, whereas brain-derived neurotrophic factor and S100B levels differed among pain conditions with structural anomalies and those without. Functional magnetic resonance imaging showed different resting state networks between patients with endometriosis and controls. In neurophysiology studies, cases had reduced pain thresholds, compared with healthy controls. Lastly, self-reported questionnaires suggested a central component of pain in women with endometriosis-related dyspareunia and associated bladder/pelvic floor tenderness. Conclusions and Relevance The management of vulvodynia and endometriosis may benefit from a new perspective, which considers their possible central etiology. It is compelling that treatment of pain starts to be considered a therapeutic goal in its own right. Target Audience Obstetricians and gynecologists, family physicians. Learning Objectives After completing this activity, the learner should be better able to describe central sensitization as a common etiology for vulvody
- Published
- 2023
7. Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
- Author
-
Cetera, G. E., Merli, C. E. M., Facchin, Federica, Viganò, P., Pesce, E., Caprara, F., Vercellini, P., Facchin F. (ORCID:0000-0001-8944-1440), Cetera, G. E., Merli, C. E. M., Facchin, Federica, Viganò, P., Pesce, E., Caprara, F., Vercellini, P., and Facchin F. (ORCID:0000-0001-8944-1440)
- Abstract
One-fourth to one-third of women with endometriosis receiving first-line hormonal treatment lacks an adequate response in terms of resolution of painful symptoms. This phenomenon has been ascribed to "progesterone resistance", an entity that was theorized to explain the gap between the ubiquity of retrograde menstruation and the 10% prevalence of endometriosis among women of reproductive age.Nevertheless, the hypothesis of progesterone resistance is not free of controversies. As our understanding of endometriosis is increasing, authors are starting to set aside the traditionally accepted tunnel vision of endometriosis as a strictly pelvic disease, opening to a more comprehensive perspective of the condition. The question is: are patients not responding to first-line treatment because they have an altered signaling pathway for such treatment, or have we been overlooking a series of other pain contributors which may not be resolved by hormonal therapy?Finding an answer to this question is evermore impelling, for two reasons mainly. Firstly, because not recognizing the presence of further pain contributors adds a delay in treatment to the already existing delay in diagnosis of endometriosis. This may lead to chronicity of the untreated pain contributors as well as causing adverse consequences on quality of life and psychological health. Secondly, misinterpreting the consequences of untreated pain contributors as a non-response to standard first-line treatment may imply the adoption of second-line medical therapies or of surgery, which may entail non-negligible side effects and may not be free of physical, psychological and socioeconomic repercussions.The current narrative review aims at providing an overview of all the possible pain contributors in endometriosis, ranging from those strictly organic to those with a greater neuro-psychological component. Including these aspects in a broader psychobiological approach may provide useful suggestions for treating those patie
- Published
- 2023
8. Topical estrogens for the treatment of superficial dyspareunia related to genitourinary syndrome of menopause in women with a history of endometriosis: A clinical dilemma.
- Author
-
Cetera GE, Merli CEM, Boero V, Caia C, and Vercellini P
- Subjects
- Female, Humans, Estrogens therapeutic use, Quality of Life, Menopause, Vagina pathology, Atrophy drug therapy, Atrophy pathology, Dyspareunia drug therapy, Dyspareunia etiology, Endometriosis complications, Endometriosis drug therapy, Endometriosis pathology
- Abstract
Estrogen withdrawal, which occurs with the cessation of ovulation, causes genitourinary syndrome of menopause in up to 50-85% of women. Symptoms may profoundly impact quality of life and sexual function, interfering with enjoyment of sex in up to three out of four individuals. Topical estrogens have been found to provide symptom relief with minimal systemic absorption and appear to be superior to systemic therapy as what regards genitourinary symptoms. However, conclusive data on their appropriateness in postmenopausal women with a history of endometriosis is not available and the hypothesis that exogenous estrogen stimulation may reactivate endometriotic foci or even promote their malignant transformation is still open. On the other hand, endometriosis affects around 10% of premenopausal women, many of which may be exposed to an acute hypoestrogenic depletion even before spontaneous menopause occurs. This considered, excluding on principle patients with a history of endometriosis from first-line treatment for vulvovaginal atrophy would mean excluding a considerable percentage of the population from adequate care. More robust evidence is urgently needed in these regards. Meanwhile, it would appear reasonable to tailor the prescription of topical hormones in these patients, taking into account the entity of symptoms and the impact such symptoms have on patients' quality of life, as well as the form of endometriosis and the possible risks hormonal may entail. Moreover, the application of estrogens on the vulva instead of the vagina could be efficacious, while outweighing the possible biological cost of hormonal treatment in women with a history of endometriosis., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.